Evidence map›Paper›PMID 32567372›Full record

Trial reportIntegrative cancer therapies

Application of Zizao Yangrong Granules for Treating Targeted Drugs-Related Skin Xerosis: A Randomized Double-Blinded Controlled Study.

Yan Mei Peng, Hua Duan, Jingyi Zhang, Chenyao Sun, Xu Zhang, Wen Shen, Shuyue Zheng, Kexin Tan, Xuejiao Jiang, Jia Li and 1 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yan Mei PengFangshan Hospital, Beijing University of Chinese Medicine, Beijing, China.ORCID 0000-0001-5739-5566
Hua DuanBeijing University of Chinese Medicine, Beijing, China.
Jingyi ZhangBeijing University of Chinese Medicine, Beijing, China.
Chenyao SunBeijing University of Chinese Medicine, Beijing, China.
Xu ZhangBeijing University of Chinese Medicine, Beijing, China.
Wen ShenBeijing University of Chinese Medicine, Beijing, China.ORCID 0000-0003-0095-0068
Shuyue ZhengBeijing University of Chinese Medicine, Beijing, China.
Kexin TanBeijing University of Chinese Medicine, Beijing, China.
Xuejiao JiangBeijing University of Chinese Medicine, Beijing, China.
Jia LiBeijing University of Chinese Medicine, Beijing, China.
Hui Juan CuiChina-Japan Friendship Hospital, Beijing, China.
Beijing University of Chinese Medicine · CNChina-Japan Friendship Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Pharmaceutical PreparationsQuality of LifeErbB ReceptorsHumansProtein Kinase InhibitorsPruritusErbB ReceptorsPharmaceutical PreparationsProtein Kinase Inhibitorsclinical trialEGFRIspruritusxerosisZizao Yangrong granules

Identifiers

PMID32567372
PMCPMC7309378
OpenAlexW3036479061

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.